Cynata Therapeutics (ASX:CYP) 3-Year EBITDA Growth Rate : -4.60% (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Cynata Therapeutics 3-Year EBITDA Growth Rate?

Cynata Therapeutics's EBITDA per Share for the six months ended in Dec. 2023 was A$-0.04.

During the past 3 years, the average EBITDA Per Share Growth Rate was -4.60% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -6.90% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was -6.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Cynata Therapeutics was 58.50% per year. The lowest was -27.60% per year. And the median was -0.50% per year.

Competitive Comparison of Cynata Therapeutics's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Cynata Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cynata Therapeutics's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cynata Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Cynata Therapeutics's 3-Year EBITDA Growth Rate falls into.

Cynata Therapeutics 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Cynata Therapeutics (ASX:CYP) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Cynata Therapeutics 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Cynata Therapeutics's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Cynata Therapeutics (ASX:CYP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cynata Therapeutics Ltd (ASX:CYP) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

51S:Germany

Address

100 Cubitt Street, Level 3, Cremorne, VIC, AUS, 3121

Website

https://www.cynata.com

Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which is branded as Cymerus. There are currently three active clinical trials taking place using Cymerus technology which are attempting to treat osteoarthritis, respiratory distress, and diabetic foot ulcers.

Cynata Therapeutics (ASX:CYP) Headlines

No Headlines